Tenax Therapeutics is focused on identifying, developing and commercializing products for the critical care market.In the U.S. alone, more than five million hospitalized patients are treated in an intensive care setting annually according to the Society of Critical Medicine.
The LEVO-CTS trial results were presented on
Sunday, March 19, 2017, at the
American College of Cardiology
66th Annual Scientific Session in Washington, D.C.